BridgeBio Oncology Therapeutics BBOT
NASDAQ BBOT
$2.84 +0.16 (+5.97%)
At close: Oct 22, 2026 · 4:00 PM EDT

BridgeBio Oncology Therapeutics (BBOT) Return on Equity [ROE] (2025 - 2026)

Updated

BridgeBio Oncology Therapeutics' Return on Equity [ROE] came in at -57.22% for Q2 2026, down 14.64 percentage points from the prior quarter.

Analysis

BridgeBio Oncology Therapeutics (BBOT) Return on Equity [ROE] (2025 - 2026) Analysis & Trends

For FY2025, BridgeBio Oncology Therapeutics' Return on Equity [ROE] was -125.46%.

  • The five-year range for quarterly Return on Equity [ROE] is -107.76% (Q3 2025) to -33.05% (Q4 2025).
  • Business Quant data shows BBOT's Return on Equity [ROE] at -42.58% (Q1 2026), -33.05% (Q4 2025) and -107.76% (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn 19.33%
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn -
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn 7.21%
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn 31.52%
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn 21.39%
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn 83.75%
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn -18.38%
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn 4.97%
10 BridgeBio Oncology Therapeutics 227.53 Mn -1.14 Bn - -57.22%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -57.22%
Mar 31, 2026 -42.58%
Dec 31, 2025 -33.05%
Sep 30, 2025 -107.76%
API Access

BridgeBio Oncology Therapeutics Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=BBOT&period=max&api_key=YOUR_API_KEY